BONE MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
- 1 April 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 49 (4) , 720-724
- https://doi.org/10.1097/00007890-199004000-00013
Abstract
Twenty-nine patients with severe aplastic anemia were entered into a study of pre- and posttransplant immunosuppressive therapy for bone marrow transplantation. Four of twenty-five previously transfused recipients prepared with cyclophosphamide 200 mg/kg and total-lymphoid irradiation 3 Gy experienced graft failure, indicating that this regimen was inadequate to ensure sustained engraftment. Posttransplant treatment with cyclosporine and methotrexate resulted in an actuarial incidence of grade .gtoreq. 2 graft-versus-host disease of 22 .+-. 16%. Actuarial survival was 78 .+-. 15%. These data indicate that more effective treatment is necessary to prevent graft failure, but since many patients can be successfully retransplanted, overall survival is comparatble to other recents.This publication has 4 references indexed in Scilit:
- THERAPY OF SEVERE APLASTIC-ANEMIA IN YOUNG-ADULTS AND CHILDREN WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION1987
- Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow TransplantationAnnals of Internal Medicine, 1987
- Marrow Transplantation for Severe Aplastic AnemiaAnnals of Internal Medicine, 1986
- TREATMENT OF SEVERE APLASTIC-ANEMIA1986